Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Enrollment on track in Ph 2 part of PYNNACLE trial of rezatapopt monotherapy in TP53 Y220C & KRAS WT advanced solid tumor patients

August 22, 2024

First Patient Dosed in Ph 2 Trial of HLX53 + Serplulimab + HANBEITAI for the First-line Treatment of Locally Advanced or Metastatic HCC Patients

August 22, 2024

Enrollment discontinued in SELECT-AML-1 Ph 2 trial of tamibarotene + venetoclax & azacitidine in newly diagnosed, unfit AML patients with RARA gene overexpression

August 22, 2024

Enrollment completed in Ph 2/3 COMPANION-002 trial of CTX-009 + paclitaxel in patients with 2L advanced Metastatic or Recurrent Biliary Tract Cancers (BTC)

August 13, 2024

Ph 3 KeyVibe-008 Trial of Vibostolimab + Pembrolizumab in Patients With Extensive-Stage SCLC to be discontinued as per IDMC recommendations

August 13, 2024

First Patient Dosed in Ph 1 Clinical Trial of AGX101

August 13, 2024

Part 1 of Deltacel-01 Ph 1 clinical trial completed; Ph 2 to be launched

August 13, 2024

Ph 1/2 PAPILIO-1 study of BCMA CAR-T GLPG5301 on hold after case of Parkinsonism

August 7, 2024

IDeate-Lung02 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed SCLC

August 7, 2024

First Patient Dosed in HEROEX-1 Ph 1a/1b Clinical Trial of NVL-330

August 7, 2024

Patient Dosing Initiated with MT-303 in Ph 1 Study for Advanced HCC

August 7, 2024

Oncology programs CUE-101 and CUE-102 deprioritized to enhance focus on autoimmune program CUE-401

August 7, 2024

First Patient Dosed in Ph 1/2 Trial of EB103 in Advanced B-cell NHL

August 7, 2024

Vobramitamab Duocarmazine Update Provided; treatment recently discontinued for TAMARACK mCRPC study participants who remained eligible for further dosing

August 7, 2024

Ph 2 Plans Announced for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

August 7, 2024

Alignment with FDA on Ph 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

August 7, 2024

Pivotal, adaptive MIRACLE Ph 3 trial designed for possible accelerated approval of Annamycin + cytarabine for the treatment of R/R AML

August 7, 2024

Cohort 3 initiated in Ph 1 Clinical Trial of NEO212 Against Malignant Brain Tumors

July 30, 2024

6th Patient dosed in ACHIEVE Study in Patients with AML

July 30, 2024

Enrollment of 80mg PK Run-In Cohort in Ph 2 EVANGELINE Trial of (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer Completed

July 30, 2024

BRG01 Enters Ph 2 Clinical Trial For Solid Tumors On Recurrent/Metastatic Nasopharyngeal Carcinoma

July 23, 2024

RMC-6236 to advance to Ph 3 testing in pancreatic cancer following encouraging results from a Ph 1 study

July 23, 2024

Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial Announced

July 17, 2024

First Patient Dosed in Global Randomized Ph 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

July 17, 2024

First Patient Dosed in GALAXIES Lung-301 Ph 3 Study

July 17, 2024
Page1 … Page7 Page8 Page9 Page10 Page11 … Page23

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.